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ABSTRACT 
 
The World Health Organization estimated that the incidence of the diabetes is 
projected to rise from 120 million in 1996 to 366 million in 2030. Diabetes mellitus 
refers to a metabolic disorder of multiple etiology characterized by chronic 
hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism 
resulting from defects in insulin secretion, insulin action, or both. The effects of 
diabetes mellitus include long–term damage, dysfunction and failure of various 
organs. Nowadays, the main issues for diabetic patients are no longer those 
associated with survival but those associated with the chronic complications of the 
diabetes. In this context, diabetic foot ulcers represent a serious medical and socio-
economic issue worldwide. To date, the best predictors of clinical outcomes are the 
presence or the absence of ischemia, infection, footwear, pressure relief, and 
overall glycaemic control. None of them, however, reflects the activity of 
endogenous repair mechanisms. Endothelial progenitor cell (EPCs) availability and 
functionality are relevant to vascular repair. It was demonstrated in patients with 
diabetes, the availability of EPCs is reduced. Different mechanisms may potentially 
be involved, including impaired mobilization, proliferation, and apoptosis..  
 Based on this consideration, the goal of my thesis is to determine the 
additive value of circulating EPCs in predicting major end-points such as mortality, 
amputation and post-angioplasty restenosis in a cohort of 120 type 2 diabetic 
patients with Critical Limb Ischemia (CLI). Moreover, we aimed to obtain 
mechanistic insights into diabetic progenitor cells impairment and to provide the 
first characterization of the EPC-associated miRNA with special respect to those 
potentially involved in the control of angiogenesis. 
To perform functional and molecular analysis normal criteria were not available so 
we decided to include in the study two different control groups: a groups of not 
diabetic CLI subjects and a group of healthy volunteer. 
To assess the first objective of this project we have to wait the end of 12 months 
follow-up (FU) so we reported an ad interim analysis of the data. To date, about 
60% of patients have reached one year FU visit and we have registered 37 
restenosis, 10 major amputations and 7 death events. We did not observe any 
statistical difference in the number of antigenically defined EPCs between 
complicated (with at least one event) and not complicated (no event) diabetic 
patients. Also the migration capacity analysis did not show difference between the 
two groups. Interestingly, our preliminary data showed a significant increase in the 
basal migration of EPC in patients with event compared with patients with no event, 
so we propose that the unspecific motility associated with altered directed 
migration may be indicative of the incapacity of the cells to find their way to injured 
tissues thereby compromising the healing process. This preliminary finding need to 
be confirmed after the end of the study. 
Second, to assess the other objective of the study we analyzed the diabetic EPC 
characteristics and functionality. We first measured by flow cytometry the 
percentage of antigenically-selected MNCs subpopulations with pro-angiogenic 
potential in all of the three groups of enrolled subject. We observed a decrease in 
CD34
pos
 and EPCs (CD45
dim
,CD34
pos
,CXCR4
pos
,KDR
pos
) in ischemic patients as 
compared to healthy volunteer. Unexpectedly however, diabetic patients showed a 
higher percentage of progenitor cells compared with non diabetic controls. 
 
 
Functionally, migration assay showed an impairment of  cell motility in chronic limb 
ischemic patients with or without diabetes compared to healthy subjects. Migration 
assay results showed an enrichment of EPCs in the controls only; these data are in 
line with those previously published on an altered migratory function of EPCs from 
diabetic patients. Mechanisms underlying the reduction of EPCs in diabetes are 
largely unknown. Weak bone marrow mobilization, impaired peripheral 
differentiation, and short survival in peripheral blood are all candidates and we 
therefore attempted to investigate the mechanisms involved in this impairment.  
Recently, miRNAs have been shown to regulate EC functions, including 
proliferation, migration and assembling in branched networks. To this aim, we 
performed a preliminary screening on EPCs from the patients enrolled and 
demonstrated that diabetes induces specific microRNAs de-regulation. Next, we 
selected two miRNAs, mir-15a and mir-16 based on their already known role in 
controlling migratory and apoptotic mechanisms in cancer. To investigate the role 
of mir-15a and mir-16, we transfected these miRNAs into healthy EPCs. We then 
analyzed cell functionality in migration and angiogenic assays and we observed 
that only co-expression of mir-15a/16 blocks EPCs migration and induce apoptosis. 
Next, we investigated if down-regulation of mir-15a/16 could restore diabetic EPC 
migratory ability. We observed that inhibition of mir-15a/16 recover FBS and SDF-1 
induced migration in diabetic EPCs but no effect was observed in apoptotic assay.  
Bionformatic analyses predict BCL2, VEGFA and AKT3 to be target genes of 
miRNA-15a and -16, which support an anti-angiogenic and pro-apoptotic role of 
these miRNAs. In diabetic EPCs and mir over-expressing EPCs, we found a down-
regulation of AKT3, a protein involved in many EPCs functions like cell cycle 
progression, migration and survival.  
This study demonstrates, for the first time, that the spontaneous migration ability of 
a well antigenically characterized MNCs subpopulation of cells with EPC 
phenotype is significantly increased in diabetic patients that manifest at least one 
major adverse event (restenosis, amputation, death). This is the first evidence 
generated in a clinical trial that EPC migration could be used as prognostic marker 
for diabetic vascular complications. At the end of the study, the analysis of the 
follow up data generated on the entire patient cohort will enable us to generate 
crucial data on the a new EPC-associated risk for diabetic CLI patients to develop 
life-threatening vascular complications. 
Second, in this work we show for the first time that mir-15a and mir-16 are key 
regulator of diabetic EPCs pro-angiogenic function. In the future we want to 
deepen the role of microRNA in diabetic dysfunction because we know that 
miRNAs have tremendous therapeutic potential for the treatment of vascular 
diseases associated with aberrant pathological angiogenesis.  
In conclusion, EPCs have recently generated considerable attention as potential 
novel prognostic biomarkers for vascular integrity, and therapeutic clinical 
approaches using these cells are ongoing. Although the role of EPCs in these 
processes is well established, the challenge for the next decade is to identify and 
evaluate methods that increase EPC homing and incorporation, thereby enabling 
targeted delivery of EPCs to a site of interest. This goal might be achieved through 
the continued characterization of EPCs in animals and humans, coupled with 
investigations of the long-term potential of EPCs in vivo. 
 
 
 
RIASSUNTO 
L‟Organizzazione Mondiale della Sanità, ha stimato che nel 2030 il numero dei 
diabetici supererà i 300 milioni, e se consideriamo che nel 1996 la stima era stata 
di circa 120 milioni, possiamo immaginare quale importanza assuma questo 
problema nei paesi occidentali. Il diabete mellito (DM) comprende un gruppo di 
disordini metabolici a diversa eziologia che influenza il metabolismo glucidico, 
lipidico e proteico ed è caratterizzato da iperglicemia cronica dovuta ad un difetto 
della secrezione di insulina o dell‟azione dell‟insulina. Ormai da molti anni, i 
progressi nella cura della malattia diabetica hanno portato ad un allungamento 
dell‟aspettativa di vita dei pazienti affetti da tale patologia che sostanzialmente non 
differisce dalla popolazione non diabetica. Oggi i problemi principali per i diabetici 
sono legati alle complicanze croniche, sia micro-angiopatiche, cioè dei piccoli vasi 
arteriosi, sia macro-angiopatiche, cioè dei grossi vasi arteriosi, derivanti da tale 
malattia. La predizione dello sviluppo della patologia si basa su dati clinici quali la 
presenza o assenza di ischemia, la presenza o assenza di infezione, il tipo di 
calzatura e il rilascio della pressione, e il controllo glicemico. Anche l‟ampiezza e la 
profondità dell‟ulcera sono fattori importanti che influenzano il decorso clinico. 
Nessuno di questi sistemi, comunque, tiene in considerazione i meccanismi 
endogeni di riparo implicati nella cicatrizzazione della ferita. La guarigione delle 
ferite è normalmente assicurata dal concorso di cellule residenti (fibrobasti, 
cheratinociti, cellule endoteliali) e cellule provenienti della circolazione, tra le quali 
un ruolo di spicco spetta alle cellule progenitrici endoteliali (EPC). Studi recenti 
hanno dimostrato che le EPC provenienti da pazienti diabetici mostrano un‟alterata 
proliferazione, adesione e incorporazione all‟interno delle strutture vascolari. I 
meccanismi responsabili di tali alterazioni rimangono per lo più ignoti. Inoltre 
mancano studi prospettici che consentano di attribuire al deficit delle EPC un 
significato prognostico in termini di evoluzione della malattia macro e 
microvascolare. 
Questo progetto si propone, come obiettivo primario, di  valutare il valore 
prognostico di cellule EPC in termini di numero, fenotipo antigenico e funzionalità 
per predire eventi quali mortalità, amputazione maggiore dell‟arto e ristenosi post-
angioplastica in una coorte di 120 pazienti affetti da diabete di tipo 2 con Ischemia 
Critica dell‟Arto (CLI), reclutati per presenza di ulcera diabetica del piede ed 
eleggibili per rivascolarizzazione mediante angioplastica. Come obiettivo 
secondario vogliamo analizzare i meccanismi che causano la disfunzionalità delle 
cellule EPC diabetiche e in particolare cercare di fornire per la prima volta un 
profilo di microRNA, potenzialmente coinvolti nei processi pro-angiogenici associati 
alle EPC diabetiche. Per questo tipo di analisi non sono presenti in letteratura 
criteri di normalità per cui abbiamo deciso di aggiungere due gruppi di controllo: un 
gruppo di soggetti non diabetici con ischemia critica dell‟arto e un gruppo di 
donatori sani. 
 
 
Per poter rispondere al primo obiettivo è necessario attendere la fine dei 12 mesi di 
follow-up; in questa tesi  quindi verranno riportati i dati ottenuti da un‟analisi 
preliminare. Ad oggi, circa il 60% dei pazienti hanno raggiunto un anno di follow-up 
al termine del quale abbiamo registrato 37 eventi di restenosi, 10 amputazioni e 7 
eventi di morte. Non abbiamo osservato nessuna differenza statisticamente 
significativa analizzando il numero di cellule EPC tra i pazienti che hanno 
presentato un evento e quelli che non l‟hanno avuto. Anche analizzando la 
capacità migratoria di queste cellule non abbiamo notato nessuna differenza 
significativa. La nostra analisi preliminare ha dimostrato un aumento significativo 
nella motilità basale delle EPC nei pazienti con eventi rispetto agli altri. Sulla base 
di questa analisi la nostra ipotesi è che l‟incapacità delle cellule diabetiche di 
giungere nel sito di ischemia sia dovuta sia ad una aumentata mobilità aspecifica 
sia ad una alterata risposta migratoria verso gli stimoli e provocando perciò un 
difetto nel processo di riparo della ferita. Questo dato, molto interessante, dovrà 
essere confermato alla fine dello studio quando tutti i pazienti avranno raggiunto i 
12 mesi di follow-up. 
Per quanto riguarda l‟obiettivo secondario dello studio abbiamo analizzato tramite 
analisi citofluorimetrica cellule MNCs subito dopo isolamento sulla base della 
espressione di marker caratteristici di alcune popolazioni pro-angiogeniche quali 
CD34 e EPC (CD45
dim
,CD34
pos
,CXCR4
pos
,KDR
pos
). I risultati ottenuti ad oggi 
mostrano una diminuzione nel numero delle cellule CD34 e delle cellule EPC nei 
pazienti ischemici rispetto ai controlli sani. Inaspettatamente, il numero di queste 
cellule nei pazienti diabetici è più alto se paragonato ai soggetti non diabetici. 
L‟analisi della funzionalità migratoria ha evidenziato una diminuzione delle capacità 
delle cellule MNC in soggetti ischemici con o senza diabete rispetto ai soggetti 
sani.  Abbiamo inoltre analizzato il fenotipo antigenico delle cellule migrate 
spontaneamente o in risposta a SDF-1a e delle cellule non migrate. L‟analisi 
citofluorimetrica dimostra una non responsività delle EPC diabetiche allo stimolo 
migratorio SDF-1 rispetto agli altri due gruppi di pazienti. Questi risultati sono in 
linea con gli studi già pubblicati e i meccanismi coinvolti in questo difetto non sono 
ancora completamente noti. Per cercare una possibile spiegazione sono state fatte 
diverse ipotesi tra le quali citiamo un debole rilascio di cellule del midollo osseo, 
un‟alterata differenziazione o una diminuita sopravvivenza di queste cellule nel 
circolo sanguigno. In questa tesi abbiamo deciso di focalizzarci sui meccanismi 
intracellulari di trasmissione del segnale. In particolare, dato il ruolo sempre più 
importante dei microRNA nel controllo dei meccanismi di regolazione delle cellule 
endoteliali, quali migrazione, proliferazione e formazione di nuovi vasi abbiamo 
effettuato una prima analisi per cercare di capire se il diabete provocasse 
modificazioni nell‟espressione di alcuni microRNA nelle EPC. Successivamente ci 
siamo concentrati su due microRNA, mir-15a e mir-16, il cui ruolo nell‟alterata 
migrazione e sopravvivenza è stato già dimostrato nelle cellule tumorali. A tale 
scopo abbiamo eseguito esperimenti di over-espressione di questi due miRNA in 
 
 
cellule EPC e abbiamo osservato come la co-espressione di mir-15a e mir-16 
riduca la risposta migratoria e induca anche il processo apoptotico in queste 
cellule. Successivamente abbiamo voluto verificare se la diminuzione di questi due 
microRNA nelle cellule EPC di pazienti diabetici potesse permettere il recupero 
della capacità migratoria di queste cellule. E‟ stato dimostrato come la down-
regolazione di mir-15a e mir-16 sia in grado di ripristinare la funzionalità migratoria 
di queste cellule. L‟analisi bioinformatica dei possibili geni bersaglio di questi 
microRNAs ha rivelato la presenza di alcuni geni coinvolti nei meccanismi di 
controllo dell‟angiogenesi e del ciclo cellulare quali VEGFa, BCL2 e AKT3. Nelle 
cellule EPC dei pazienti ischemici con o senza diabete e nelle cellule over-
esprimenti mir-15a e mir-16 abbiamo osservato una diminuzione significativa dei 
livelli di AKT3, proteina coinvolta in numerosi processi di migrazione e 
proliferazione cellulare. Sulla base dei risultati che abbiamo ottenuto ulteriori studi 
sono necessari per verificare il coinvolgimento di altri geni bersaglio e per 
investigare su un possibile ruolo nella disfunzione causata dal diabete. In 
particolare la nostra attenzione sarà rivolta ai meccanismi di trasduzione del 
segnale che coinvolgono AKT e la proteina eNOS.  
Questo progetto dimostra, per la prima volta, che la migrazione spontanea di una 
sottopopolazione di MNC definite antigenicamente come EPC è aumentata in 
pazienti diabetici che hanno avuto un evento quali restenosi, amputazioni e morte. 
Sulla base di questi risultati è possibile ipotizzare l‟utilizzo della migrazione basale 
delle EPC come fattore prognostico per prevenire le complicanze vascolari di 
pazienti diabetici. In questa tesi abbiamo anche dimostrato che mir-15a e mir-16 
sono regolatori chiave delle funzioni pro-angiogeniche delle cellule EPC. In futuro 
vogliamo approfondire il ruolo dei microRNA nella disfunzione diabetica anche in 
quanto è ormai noto che i microRNA hanno un enorme potenziale terapeutico per il 
trattamento di patologie caratterizzate da alterata angiogenesi.  
Negli ultimi anni è emerso come  i microRNA svolgano un ruolo fondamentale nel 
trattamento di patologie vascolari in cui sono presenti alterati meccanismi pro-
angiogenici e questo suscita il nostro interesse per meglio comprendere il ruolo dei 
microRNA nella patologia diabetica soprattutto se complicata da problemi 
vascolari. L‟utilizzo di antagonisti di microRNAs che controllano l‟angiogenesi, in 
grado di essere indirizzati nei siti di ischemia potrebbe essere un valido approccio 
per cercare di prevenire le complicanze vascolari di alcune malattie. 
In conclusione,  il nostro studio mostra il ruolo chiave delle EPC nei meccanismi di 
angiogenesi e suggerisce il loro potenziale utilizzo come biomarcatore dell‟integrità 
vascolare. Approcci di terapia genica che utilizzano queste cellule sono infatti già in 
corso. Il futuro della ricerca consiste quindi, nell‟individuare metodi per migliorare la 
capacità migratoria e di integrazione di queste EPC  nei siti di interesse 
combinando tecniche sperimentali in vitro e in vivo. 
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1. INTRODUCTION 
Diabetes is one of the most challenging health problems in the 21
st
 century. The 
prevalence of diabetes for all age-groups worldwide was estimated to be 2.8% in 
2000 and 4.4% in 2030. The total number of people with diabetes is projected to 
rise from 171 million in 2000 to 366 million in 2030 (Figure 1).  
 
Figure 1. Global projection for the number of people with diabetes (20-79 age 
group) 2007-2025 (millions) 
 
1.1 Etiology of Diabetes 
 
World Health Organization in 1999 described Diabetes Mellitus as a metabolic 
disorder of multiple etiology characterized by chronic hyperglycaemia with 
disturbances of carbohydrate, fat and protein metabolism resulting from defects in 
insulin secretion, insulin action, or both. The effects of diabetes mellitus include 
long–term damage, dysfunction and failure of various organs. 
Diabetes mellitus is classified on the basis of etiology and clinical presentation of 
the disorder as: type 1 diabetes, type 2 diabetes, gestational diabetes mellitus 
(GDM), and other specific types. 
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1.1.1 Type 1 diabetes 
Type 1 diabetes is sometimes called insulin-dependent, immune-mediated or 
juvenile-onset diabetes. It is caused by destruction of the insulin-producing cells of 
the pancreas, typically due to an auto-immune reaction, where they are attacked by 
the body's defense system. The beta cells of the pancreas therefore produce little 
or no insulin, the hormone that allows glucose to enter body cells. The disease can 
affect people of any age, but usually occurs in children or young adults. Type 1 
diabetes is one of the most common endocrine and metabolic conditions in 
childhood. People with type 1 diabetes need injections of insulin every day in order 
to control the levels of glucose in their blood. Without insulin, people with type 1 
diabetes will die. The incidence of type 1 diabetes is increasing, the reasons for 
which are unclear but are likely to be mainly due to changes in environmental risk 
factors. Environmental risk factors, increased height and weight, increased 
maternal age at delivery, and possibly some aspects of diet and exposure to some 
viral infections may initiate autoimmunity or accelerate an already ongoing beta cell 
destruction. 
 
1.1.2 Type 2 diabetes  
Type 2 diabetes constitutes about 85 to 95% of all diabetes in developed countries. 
It is characterized by insulin resistance and relative insulin deficiency, either of 
which may be present at the time that diabetes becomes clinically manifest. The 
diagnosis of type 2 diabetes usually occurs after the age of 40 years but could 
occur earlier, especially in populations with high diabetes prevalence. Type 2 
diabetes can remain asymptomatic for many years and the diagnosis is often made 
from associated complications or incidentally through an abnormal blood or urine 
glucose test. There are several possible factors in the development of type 2 
diabetes as obesity, diet, physical inactivity, increasing age and family history of 
diabetes. In contrast to type 1 diabetes, people with type 2 diabetes are not 
dependent on exogenous insulin but may require insulin for control of 
hyperglycaemia if this is not achieved with diet alone or with oral hypoglycaemic 
agents. 
 
1.1.3 Gestational diabetes 
Gestational diabetes mellitus (GDM) is a glucose intolerance of varying degrees of 
severity which starts or is first recognized during pregnancy. The definition applies 
regardless of whether insulin is used for treatment or if the condition persists after 
pregnancy. GDM is also associated with increased risk of obesity and abnormal 
glucose metabolism during childhood and adult life in the offspring. 
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1.1.4 Diabetic complications 
New progress in the treatment leading to control of hyperglycaemia has resulted in 
increased life expectation. However, quality of life remains poor due to associated 
complications, especially affecting the cardiovascular system. These include 
macroangiopathy, large arterial vessels angiopathies (ischemic cardiopathy, 
arteriopathy of the lower limbs, arteriopathy of the supraortic trunks), 
microangiopathy, angiopathies of the small arterial vessels (retinopathy, 
nephropathy, neuropathy) (Figure 2). The risk for developing complications is 
influenced by many factors including duration of diabetes and genetic factors. 
Current treatments have resulted in only a partial reduction in cardiovascular risk, 
and the management of these conditions remains a major unmet need for those 
with diabetes. 
 
Figure 2. The major diabetic complications. 
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1.1.4.1 Cardiovascular disease 
Cardiovascular disease (CVD) is the major cause of death in diabetes, accounting 
for 50% or more of all diabetes fatalities and disability. CVD include angina, 
myocardial infarction (heart attack), stroke, peripheral artery disease, and 
congestive heart failure (CHF). The pathogenesis of CVD associated with diabetes 
is not yet fully understood. However, because atherosclerotic macrovascular 
complications occur at an earlier age and with greater severity in people with 
diabetes, it is likely that its pathogenesis is directly influenced by the diabetic state. 
Current American Diabetes Association guidelines recommend aggressive 
treatment for dyslipidemia in diabetic patients, particularly in those with elevated 
LDL cholesterol levels. Tight glycaemic control achieved with diet, exercise, and 
some antidiabetic agents may substantially improve the lipid profile and reduce the 
risk of CVD in some patients. However, most patients will require the use of 
intensive lipid-lowering therapy to reduce their cardiovascular risk, most commonly 
with one of the statins or fibric acid derivatives.  
 
1.1.4.2  Nephropathy 
Diabetes has become the most common single cause of end-stage renal disease in 
the U.S.A and Europe; this is due to the facts that 1) diabetes, particularly type 2, is 
increasing in prevalence; 2) diabetic patients now live longer.  
The earliest clinical evidence of nephropathy is the appearance of increased urine 
albumin levels referred to as microalbuminuria, and patients with microalbuminuria 
are referred to as having incipient nephropathy. Annual screening for 
microalbuminuria allows the identification of patients with nephropathy at a point 
very early in its course. Improving glycaemic control, aggressive antihypertensive 
treatment, and the use of angiotensin converting enzyme (ACE) inhibitors or 
angiotensin II receptor blockers (ARBs) slow the rate of progression of 
nephropathy. 
 
1.1.4.3  Neuropathy 
Diabetic neuropathy is defined as the presence of symptoms and/or signs of 
peripheral nerve dysfunction in people with diabetes, after exclusion of other 
causes. When blood glucose and blood pressure are not controlled, diabetes can 
harm the nerves. The most commonly affected area is the feet and legs. Nerve 
damage in these areas is called peripheral neuropathy and could manifest in many 
ways including loss of feeling in the feet and toes. Peripheral somatic neuropathy, 
together with peripheral vasculopathy, is the most frequent cause in the formation 
of diabetic foot ulcers. Autonomic neuropathy contributes to the development of 
diabetic cardiomyopathy, silent cardiac ischemia, and cardiac arrhythmias. 
Cardiovascular manifestations of autonomic neuropathy comprise resting 
tachycardia and orthostatic hypotension. Screening procedures today allow an 
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early diagnosis of sub-clinical neuropathy, but their use for prevention has not yet 
entered the common clinical practice. The consequent social costs of an omitted 
early diagnosis are relevant, considering that several studies and meta-analyses 
indicate an increase of 3.5 fold in the relative risk of mortality in diabetic patients 
with cardiac autonomic neuropathy. However, despite the high relevance of this 
phenomenon, the mechanisms underlying the increase in mortality have not been 
yet completely understood.  
The genesis of the dysautonomy seems to be multifactorial with evidence of the 
role of oxidative stress, deficit of trophic factors such as nerve growth factor (NGF) 
and microangiopathy with endonerval ischemia. In the absence of a target for a 
real mechanistic cure, strict glycaemic control is the only therapeutic action to 
prevent the evolution of neurological damage. 
 
1.1.4.4  Retinopathy 
Diabetic retinopathy is one of the main causes of visual loss in individuals aged 20-
64 years old and is present in more than 77% of patients with diabetes mellitus 
who survive for over 20 years with the disease [1]. Diabetes can harm sight and 
cause blindness in several ways. The most common cause of blindness in diabetes 
is macular edema, caused by fluid build-up behind the retina of the eye. A more 
common complication is background and proliferative retinopathy, which can cause 
blindness as a result of repeated haemorrhages at the back of the eye. Diabetes 
also increases the risk of cataracts and glaucoma. 
 
1.1.4.5  Diabetic Foot 
Among the complications of diabetes "diabetic foot" plays an increasingly important 
role; this is definitely the complication which leads to the highest number of hospital 
admissions and whose cost is enormous. If we consider the forecasts of the World 
Health Organization for 2030, it is easy to imagine the potential extent of the 
problem: estimates of this pathology actually state that during their lifetime 
approximately 15% of diabetic patients will have a foot ulcer which requires 
medical treatment. The most important problem associated with a foot ulcer in 
diabetic patients is the risk of major amputation, i.e. carried out above the ankle; 
although the diabetic population represents around 3% of the general population, 
over 50% of all major amputations actually involve diabetic patients. Data from 
several studies have documented that foot ulcers precede approximately 85% of all 
amputations performed in patients with diabetes. Risk of ulceration and amputation 
increases 2- to 4-fold with both age and duration of diabetes.  
Hence, it is obvious that reducing the number of amputations is a fundamental aim 
in the treatment of diabetic patients. 
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Clinical Definition 
The term diabetic foot is used when diabetic neuropathy or arteriopathy of the 
lower limbs compromises the function or structure of the foot.  
The first is defined neuropathic foot while the second one is ischemic foot. 
These conditions are extremely different from each other: however in most 
patients, especially those of advanced age, neuropathy and vasculopathy coexist 
and the term neuroischemic foot is therefore used.  
 
Neuropathic foot 
Diabetic neuropathy affects the sensory nerves (sensory neuropathy) the motor 
nerves (motor neuropathy) and the vegetative nerves (autonomic neuropathy); the 
neuropathic foot is therefore a foot in which the diabetic neuropathy has altered the 
equilibrium of the muscles, the perception of stimuli, vegetative autoregulation, 
namely all three nerve components. The ideal treatment would be to identify all 
those diabetic patients suffering from neuropathy in order to implement a 
prevention program which could succeed in reducing the risk of an ulcerative 
wound. Once an ulcer is formed,  the requirement is to stimulate the healing as fast 
as possible.   
Fundamentally the treatment of the neuropathic plantar ulcer is based on three 
points:  
 local treatment of the wound (cleaning the ulcer plus dressing)  
 the treatment of any infections  
 the removal of the ulcerative wound (preventing this worsening on account 
of the weight of the body while the subject is walking)  
 
It is of fundamental importance to point out the fact that the failure to implement 
even one of these therapeutic stages drastically reduces the likelihood of the 
ulcerative wound healing. 
 
Ischemic Foot 
The histological characteristics of peripheral obstructive arteriopathy (POA) in 
diabetic patients do not differ substantially from the arteriopathy of the non-diabetic 
population. However the clinical characteristics are very different; in diabetic 
patients, arteriopathy is more frequent, early, rapidly progressive, does not exclude 
women, even those of fertile age, affects both legs and mainly involves the arteries 
under the knee. A typical characteristic of the diabetic patient is often the lack of an 
earlier symptom of peripheral arteriopathy.  
International criteria for diagnosing chronic critical ischemia have been re-
established several times in the light of new information and new studies.  
The most recent criteria are those of the TASC (TransAtlantic Inter-Society 
Consensus) published in January 2000.  
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TASC criteria are: subject with ulcer or gangrene or pain at rest, pressure on the 
ankle < 50-70 mmHg  or on the big toe < 30-50 mmHg or transcutaneous oximetry 
< 30-50 mmHg.  
Foot ulceration and amputation affect the quality of life and create an economic 
burden for both the patient and the health care system. Revascularization of the 
diabetic foot is often complicated by restenosis and thrombosis events, which 
account for the excess of limb amputation. 
At present, two well-established systems are used for wound classification: the 1) 
Wagner system and 2) the new University of Texas (UT) system, with the latter 
being a better predictor
 
of outcome.  
 
1) The Meggitt–Wagner classification is the most well-known and validated system 
for foot ulcers. It is simple to use and has been validated in a number of studies. 
Higher grades are directly related to increased risk for lower limb amputation. It is 
considered the gold-standard, against which other systems should be validated 
(Table 1) 
Grade Description of the ulcer 
Grade 0 
Pre- or post-ulcerative lesion completely 
epithelialized 
Grade 1 
Superficial, full thickness ulcer limited to the 
dermis, not extending to the subcutis 
Grade 2 
Ulcer of the skin extending through the subcutis 
with exposed tendon or bone and without 
osteomyelitis or abscess formation 
Grade 3 
Deep ulcers with osteomyelitis or abscess 
formation 
Grade 4 Localized gangrene of the toes or the forefoot 
Grade 5 Foot with extensive gangrene 
Table 1.  The Meggitt- Wagner classification 
 
2) The University of Texas classification system for diabetic foot wounds has 
recently been proposed and validated by the University of Texas. This system 
evaluates both depth of the ulcer as in Meggitt–Wagner classification system and 
presence of infection and ischemia. (Table 2). It is simple to use and shown to 
predict more accurately the outcome of an ulcer (healing or amputation). 
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Grade 
Stage 0 1 2 3 
A 
Pre- or post-
ulcerative 
lesion 
Completely 
epithelialized 
Superficial 
wound not 
involving 
tendon, 
capsule or 
bone 
Wound 
penetrating to 
tendon or 
capsule 
Wound 
penetrating to 
bone or joint 
B With infection With infection With infection With infection 
C With ischemia With ischemia With ischemia With ischemia 
D 
With infection 
and ischemia 
With infection 
and ischemia 
With infection 
and ischemia 
With infection 
and ischemia 
Table 2.  The University of Texas classification system for diabetic foot wounds 
 
Any valid classification system of foot ulcers should facilitate appropriate treatment, 
simplify monitoring of healing progress and serve as a communication code across 
specialties in standardized terms.  
The “Meggit-Wagner” classification do not take into account the presence of 
ischemia and infection so  the “University of Texas classification system” offers 
many advantages over the other system and is the most appropriate system 
devised to date. The two systems do not describe the location of the ulcer and 
importantly they do not consider parameters related to the patients as poor foot 
care, emotional upset and denial. To ameliorate these classifications further 
systems should include other parameters such as location of the ulcer, foot 
deformities and other factors which may be related to the outcome of an ulcer.  
 
Based on all these considerations the prediction of clinical outcome of diabetic foot 
relies only on clinical data, including the presence or absence of infection, footwear
 
and pressure relief, and overall glycemic control. However, none of these methods 
takes into account the endogenous repair mechanisms implicated in wound 
cicatrisation of the ulcers that are impaired in diabetic patients.  
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1.2. Endothelial Progenitor Cells (EPCs) 
Improvement of neovascularization after critical ischemia is an important novel 
therapeutic strategy. Growth of new blood vessel in the adult occurs through 
arteriogenesis, angiogenesis or vasculogenesis [2]. Arteriogenesis is defined as 
the growth of collateral vessels, whereas angiogenesis refers to the growth of new 
capillaries by sprouting of preexisting vessels through migration and proliferation of 
mature endothelial cells (ECs). The concept of vasculogenesis was originally 
described by Sabin and others, who investigated the embryonic de novo blood 
vessel formation and assigned the term “angioblast” to the endothelial cell 
precursor. Now, the term “vasculogenesis” is also used to describe adult blood 
vessel formation, referring to the mobilization of bone marrow– derived endothelial 
stem cells, which home to sites of ischemia and contribute to new blood vessel 
formation [3] (Figure 3)  
 
 
Figure 3. Neovascularization encompasses both angiogenesis and vasculogenesis 
[4]. 
The finding that vasculogenesis also contributes to blood vessel formation in the 
adult offers novel therapeutic strategies for the use of cultivated circulating 
endothelial progenitor cells (EPCs) or their precursors for cell therapy of tissue 
ischemia. Endothelial progenitor cells (EPCs) were identified in 1997 by Asahara 
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and colleagues in human peripheral blood as CD34 positive mononuclear cells 
(MNC) [5]. In this work they demonstrated that, in vitro, these cells have markers of 
endothelial cells and, in a mouse model of limb ischemia, EPCs incorporated into 
sites of active angiogenesis. These findings suggest that EPCs may be useful for 
augmenting collateral vessel growth to ischemic tissues and for delivering anti- or 
pro-angiogenic agents to sites of pathologic angiogenesis. Based on literature data 
EPCs are difficult to define precisely because of lack of consensus regarding the 
best EPCs source, the optimal culture techniques, and the phenotypes and 
characteristics that are crucial for EPCs identity. Some groups identified EPCs in 
culture as early outgrowth cells (also called circulating angiogenic cells) or late 
outgrowth cells (endothelial colony forming cells) [6]. EPCs have also been 
characterized by the uptake of diacetylated low-density lipoprotein (LDL), by the 
binding of fluorescently labeled Ulex europaeus agglutinin 1 lectin, or by in-vitro 
and in-vivo functional assays, such as colony formation, tube formation, and 
vascular integration. Another conventional method of EPCs identification is based 
on the coexpression of hematopoietic stem-cell markers (e.g., CD133, CD34) and 
endothelial-cell markers (e.g., vascular endothelial growth factor [VEGF] receptor-2 
or kinase-insert domain receptor [KDR], von Willebrand factor [vWF], endothelial 
nitric oxide synthase [eNOS]) [7]. Today, scientists accept the definition that EPCs 
consist of two different subpopulations, termed early and late EPCs [8]. Although 
both EPCs are derived from MNC and express endothelial cell markers, they have 
different morphologies and growth patterns [9]. Early EPCs exhibit a spindle-like 
morphology and the majority of them are derived from CD14(+) subpopulations. 
Late EPCs, named after their late outgrowth potential, exhibit a cobblestone 
morphology and are derived from CD14(−) fractions. These two populations have 
been characterized for production of vascular endothelial growth factor (VEGF), 
VEGF receptor expression, cytokine secretion, and tube forming activity in vitro 
and in vivo [10]. Our groups defined EPCs as pro-angiogenic circulating progenitor 
cells that co-express CD34, KDR and CXCR4, the stromal cell derived-factor (SDF-
1) receptor. [11] 
Recent studies indicated that bone marrow is the major source of EPCs and that 
endogenous mobilization of EPCs from the bone marrow into the peripheral blood 
occurs in response to a physiologic or pathological need for neovascularization and 
contribute to new blood vessel formation [3, 12]. EPCs recruitment requires a 
coordinated sequence of events, including chemoattraction, adhesion, and 
migration. EPCs indirectly support neovascularization by a paracrine mechanism, 
i.e. they contribute to vascular growth primarily by secreting growth factors, 
chemokines, cytokines that inhibit cell death, enhance cell proliferation, activate 
stem/progenitor cells already present in the ischemic tissue and recruit additional 
progenitor cells to the injury site [13-16]. 
Detractors of the EPCs isolation protocols argue that most of the available 
literature should be critically revisited in light of the recent observation that EPCs 
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have no true progenitor or endothelial properties. Based on all these problems  the 
original antigenic phenotype of EPCs, CD34+KDR+, is still the best compromise in 
terms of specificity and sensitivity in the clinical setting, even if it might not be 
completely distinguishable between EPCs, mature endothelial cells and 
haematopoietic progenitors cells. 
 
1.2.1 Diabetes and EPCs 
The inability of EPCs to maintain a normal endothelial homoeostasis and to 
promote the development of new vessels could lead to accelerated vascular 
disease and ageing and could block compensatory angiogenesis, thus favoring the 
development and progression of ischemic syndromes. Interestingly, EPCs 
alterations have been shown in subjects with diabetes, hypertension, dyslipidemia, 
cigarette smoking, obesity and family history of cardiovascular disease [17]. 
Endothelial dysfunction and damage is an early and widespread complication in 
patients with diabetes and it is also the first stage in the pathogenesis of 
atherosclerosis. It has been recognized that the endothelial repair process also 
plays an important role in determining overall vascular health. A damaged 
endothelium is repaired by being partially covered by resident endothelial cells plus 
the contribution of circulating EPCs. EPCs reduction and dysfunction has been 
shown in type 1 and type 2 diabetes: Tepper et al. found that early EPCs from 
patients with type 2 diabetes exhibit impaired proliferation, adhesion and 
incorporation into vascular structures [18]; Loomans et al. obtained similar results 
in patients with type 1 diabetes, by showing a reduced number of early cultured 
EPCs compared with control subjects [19].  
Recently, Egan et al. demonstrated also a reduction in several different subtypes of 
EPCs in patients with T2D compared to controls.[20] 
This reduction is probably involved in the pathogenesis of vascular complications of 
diabetes, but there are few data on this topic currently available in the literature. In 
particular Fadini and his collaborators showed a decrease of EPCs levels in 
diabetic patients which is associated with a high risk of peripheral vascular 
complications [21]. 
EPCs have been shown to be altered in all diabetic complications and they appear 
as a major common underlying pathogenic mechanism [22]. In addition to being a 
potential pathogenic actor and a marker of the vascular burden, reduced EPCs can 
be also considered a surrogate marker of increased risk of future adverse events. It 
has been shown that a low baseline progenitor cell count predicts cardiovascular 
events in patients with cardiovascular disease [23], chronic renal failure [24] or the 
metabolic syndrome [25]. 
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1.2.2 Mechanisms of EPCs mobilization and homing  
Under steady state conditions, small numbers of EPCs constantly leave the BM, 
enter tissues, and travel back to the BM or peripheral niches via the blood and 
lymph [26]. EPCs liberation into the blood increases dramatically after an acute 
injury or ischemia, thereby providing large numbers of reparative units to the 
damaged tissue and thus facilitate healing. The travel of EPCs from the BM into the 
activated tissue  is guided by the interplay of several molecular and cellular 
mechanisms. Initially, the disruption of anchorage mechanisms between EPCs and 
stromal cells allow the SC to leave the niche, while increased concentrations of 
chemotactic substances outside the BM niche provide a migratory stimulus [27] 
[28]. Homing to the target tissue is modulated by a spectrum of mechanisms: loose 
adhesion via selectins as well as membrane bound growth factors and their 
ligands/receptors, mediate the rolling movement of the cells along the endothelial 
layer. Subsequently, integrins mediate invasion of the target tissue, via their 
interaction with endothelial surface molecules and matrix proteins[29, 30]. Finally, 
the directional migration of recruited EPCs within the target tissue and their 
organization into niche-like structures contribute to stable engraftment for tissue 
repair (Figure 4).  
 
 
Figure 4. Overview of endogenous mechanisms modulating EPCs mobilization 
from the BM and recruitment to the target tissue. 
  
The most relevant chemokines involved in these processes is Stromal Derived 
Factor-1α (SDF-1a/CXCL12). It has been shown that its expression is up-regulated 
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during ischemia [27]. Inhibition of CXCR4 partially blocks the homing of progenitor 
cells to the ischemic myocardium [31]. Other studies demonstrated that inhibition of 
its receptor CXCR4 significantly reduced SDF-1 induced adhesion of EPCs to 
mature endothelial monolayer, the migration of EPCs in vitro [27], and the in vivo 
EPCs homing in a model of hind limb ischemia [32]. Moreover over-expression of 
SDF-1 enhanced progenitor cell homing and incorporation into ischemic tissue [33, 
34], supporting the idea that SDF-1 play a crucial role for recruitment of circulating 
progenitor cells. Despite the important role of CXCR4/SDF-1a in EPCs migration, 
proliferation, survival and angiogenesis, relatively little is known about the signal 
transduction pathways that mediate these effects in EPCs. Studies in many cell 
types have implicated both PI3K/Akt and MAPK/ERK signal transduction pathways 
in the control of directional cell migration and the sensing chemoattractant 
gradients by the cell. Zheng and colleagues showed that SDF-1a-induced 
migration of EPCs was CXCR4 dependent using AMD3100, a CXCR4 antagonist. 
Their results demonstrated that PI3K/AKT/eNOS is crucial for SDF-1 mediated 
migration of EPCs [35] (Figure 5). 
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Figure 5.  Intracellular signalling pathways for migration.[36] 
 
Recent data determined the involvement of additional other chemokines as IL-
8/Gro-α and its cellular receptor CXCR2, in the homing of CD34 progenitor cells to 
the ischemic myocardium [37]. Furthermore, ischemia-induced VEGFa acts as a 
chemoattractant to EPCs [38]. Interestingly, VEGF is sufficient to induce the 
recruitment of progenitor cells and their perivascular localization via induction of 
SDF-1 expression by perivascular myofibroblasts suggesting that different 
cytokines may cooperate during homing of progenitors cells [39]. 
All these data suggest that chemokines like SDF-1a, IL-8 and probably others are 
involved in the trafficking of EPCs from the bloodstream to ischemic tissues [40]. 
So far, mechanistic research has focused mainly on SDF-1/CXCR4 signaling 
during the recruitment of angio-supportive cells. Nevertheless, kinins play a key 
role in governing processes of the vessel wall and it was demonstrated their 
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necessity for recruiting circulating pro-angiogenic cells. In particular, EPCs use 
proteases, like MMPs and cathepsins, to disrupt the endothelial matrix in the 
initiation of reparative neovascularization. Madeddu‟s group has proposed another 
member of this class, human tissue kallikrein 1 (hKLK1), as a potent factor for 
promotion of therapeutic neovascularization, as indicated by studies in animal 
models of ischemia [41, 42].  hKLK1 can exert its effects via kininogen cleavage, 
thus generating kinins, as bradykinin (BK) or kallidin (kDa). Kinins, such as BK, 
activate kinin-B2 receptors (B2R), which are constitutively expressed on endothelial 
cells (ECs), and kinin-B1 receptors (B1R), whose expression is induced under 
stress conditions. (Figure 6) 
 
 
 
 
Figure 6. Components of kallikrein-kinin system [43] 
 
Overexpression of hKLK1 promotes a robust and persistent neovascularization 
through kinin-mediated activation of the Akt-eNOS pathway, and has recently been 
shown to display tissue specific VEGF dependency. In Stone work, it was 
demonstrated the fundamental role of endogenous tissue kallikrein in vascular 
repair and provide novel information on the cellular and molecular mechanisms 
responsible for the robust arterialization induced by hKLK1 overexpression [44]. 
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Krankel et al. recently demonstrated the importance of the B2R in the recruitment of 
circulating pro-angiogenic cell types as well as in the subsequent mounting of 
revascularization and recovery of blood flow in ischemic tissue [45]. We also 
revealed that hKLK1 coupling to B2R signaling is essential for EPCs invasive 
capacity. Our results showed for the first time that human EPCs are equipped with 
active endogenous hKLK1 and that hKLK1 is crucial for EPCs invasive and 
proangiogenic activities by both protease- and kinin receptor-mediated 
mechanisms. Finally, this study demonstrated that kinin kallikrein system faulty 
components need to be repaired to restore the pristine EPCs function in diabetes, 
thus providing the first proof of concept for multiple gene engineering of a pathway 
crucially implicated in angiogenesis. [11] 
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1.3. MicroRNA: potential new regulators for EPCs functions in 
diabetes 
MicroRNAs (miRNAs) are a class of endogenous, small, non-coding RNAs, which 
have been recently discovered to play a major role in gene regulation, including of 
mammalian cells [46]. MiRNAs characterization has become a major interest in 
biology and medicine, with implications for the detection and treatment of different 
pathologies. MicroRNAs are abundant in the vascular system, where they have key 
roles in development and are likely to be important mediators of vascular system 
diseases. So far, more than 1400 human miRNA sequences [47] have been 
identified. A single miRNA can target hundreds of mRNA transcripts for 
translational repression, mRNA degradation, or inducing mRNA instability. 
Consequently, accurately determining the full repertoire of miRNA targets is 
essential for knowing miRNA functional characteristics. MiRNA target gene 
identification is currently a major bottleneck in miRNA research [48].  
MiRNAs are single-stranded RNAs of ~22 nucleotides and are found in both plants 
and animals. They negatively regulate their targets in one of two ways depending 
on the degree of complementarities between the miRNA and the target [49]. First, 
miRNAs that bind with perfect or nearly perfect complementarities to protein coding 
mRNA sequences induce the RNA-mediated interference (RNAi) pathway. Briefly, 
mRNA transcripts are cleaved by ribonucleases in the miRNA-associated, 
multiprotein RNAinduced-silencing complex (miRISC), which results in the 
degradation of target mRNAs. This mechanism of miRNA-mediated gene silencing 
is commonly found in plants, but miRNA-directed mRNA cleavage has also been 
shown to occur in mammals [50]. However, most animal miRNAs are thought to 
use a second mechanism of gene regulation that does not involve the cleavage of 
their mRNA targets. These miRNAs exert their regulatory effects by binding to 
imperfect complementary sites within the 3′ untranslated regions (UTRs) of their 
mRNA targets, and they repress target-gene expression post-transcriptionally, 
apparently at the level of translation, through a RISC complex that is similar to, or 
possibly identical with, the one that is used for the RNAi pathway. Consistent with 
translational control, miRNAs that use this mechanism reduce the protein levels of 
their target genes, but the mRNA levels of these genes are barely affected. 
However, recent findings indicate that miRNAs that share only partial 
complementarities with their targets can also induce mRNA degradation, but it is 
unclear if translational inhibition precedes destabilization of the gene targets in 
these cases. The biogenesis of miRNAs has only recently been elucidated. 
miRNAs, which generally seem to be transcribed by RNA polymerase II, are initially 
made as large RNA precursors that are called pri-miRNAs. The pri-miRNAs are 
processed in the nucleus by the RNase III enzyme, Drosha, and the double-
stranded- RNA-binding protein, Pasha (also known as DGCR8), into ~70-
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nucleotide pre-miRNAs, which fold into imperfect stem-loop structures. The pre-
miRNAs are then exported into the cytoplasm by the RAN GTP dependent 
transporter exportin 5 and undergo an additional processing step in which a 
double- stranded RNA of ~22 nucleotides in length, referred to as the 
miRNA:miRNA* duplex, is excised from the pre-miRNA hairpin by another RNAse 
III enzyme, Dicer. Subsequently, the miRNA:miRNA* duplex is incorporated into 
the miRISC complex. The mature miRNA strand is preferentially retained in the 
functional miRISC complex and negatively regulates its target genes (Figure 7).  
 
 
Figura 7. MicroRNA biogenesis [50] 
 
The first miRNA gene lin-4, was identified in Caenorhabditis elegans and controls 
the timing and progression of the nematode life cycle [51]. 
Most human miRNAs are found within introns of either protein-coding or noncoding 
mRNA transcripts. The remaining miRNAs are either located far from other 
transcripts in the genome, within the exons of noncoding mRNA genes or within the 
3′ UTRs of mRNA genes, or they are clustered with other miRNA genes, including 
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a cluster on chromosome 19 that is comprised of 54 novel miRNAs. MiRNAs can 
be grouped into families on the basis of sequence homology, which is found 
primarily at the 5′ end of the mature miRNAs, but whether members of the same 
miRNA family control similar biological events remains to be seen. Several studies 
have indicated that the 5′ end of the miRNA is crucial for the stability and proper 
loading of the miRNA into the miRISC complex, and this end is also important for 
biological function. Therefore, most bioinformatic algorithms use a „miRNA seed‟ 
that encompasses the first 2–8 bases of the mature miRNA sequence to search for 
complementarities to sequences in the 3′ UTR of all expressed genes. These 
studies have revealed that a single miRNA might bind to as many as 200 gene 
targets and that these targets can be diverse in their function; they include 
transcription factors, secreted factors, receptors and transporters. [50] 
 
1.3.1 MiRNAs and diabetes 
The list of diseases in which dysregulation of miRNAs has been implicated is 
constantly growing. Compared with cancer, far less is known about the role of 
miRNAs in diabetes and its complications. The levels of several miRNAs have 
been reported to be modified in different animal models of diabetes. miR-34a and 
miR-146a expression is increased in pancreatic islets isolated from diabetic obese 
mice[52]. Changes in miRNA expression were also observed in different tissues of 
Goto-Kakizaki (GK) rats, a non-obese model of type 2 diabetes. In the muscle of 
these rats, two members of the miR-29 family, miR-29a and miR-29b are 
upregulated compared with healthy rats [53]. 
MicroRNAs also seem to be involved in diabetes complications. Recent studies 
demonstrated an involvement in diabetic nephropathy of mir-93, which is regulated 
by hyperglycemia and controls VEGFa expression [54]. Other groups 
demonstrated that mir-133 is an important factor for the developing of diabetic 
cardiomyopathy [55].  
Zampetaki et al performed the first plasma microRNAs signature in patients with 
type-2 diabetes in a large population cohort. They found 5 microRNAs (miR-15a, 
miR-126, miR-320, miR-223, miR-28-3p) to be deregulated in patients with 
diabetes[56].  
 
1.3.2 MicroRNAs and angiogenesis 
First evidence of miRNAs involvement in the regulation of angiogenesis was found 
by the inhibition of Dicer and Drosha, two key nucleases involved in miRNA 
maturation. Knockdown of Dicer or Drosha in vitro inhibits ECs capillary sprouting, 
migration and tubulogenesis, altering the expression of several key regulators of 
endothelial biology and angiogenesis [57, 58]. Poliseno et al. identified, for the first 
time, an endothelial cells miRNAs profile; in particular he found a group of 15 highly 
expressed miRNAs that could potentially negatively regulate the expression of 
angiogenic factors [59]. Several microRNAs were described by other groups to be 
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expressed in EC under normal condition. Moreover, this microRNA expression 
profile could change if EC are studied in stress conditions or EC are derived from 
diseased organism [60]. Angiogenesis-regulatory miRNAs can be divided into the 
pro-angiogenic miRNAs that promote angiogenesis and the anti-angiogenic 
miRNAs that inhibits angiogenesis: 
 pro-angiogenic microRNAs: 
mir-126 has been shown to be highly expressed in human endothelial 
cells. It‟s important for maintaining vascular integrity during ongoing 
angiogenesis, targeting SPRED1 and PIK3R2, two negative regulators of 
VEGF signaling [61]; 
mir-130a expression was undetectable in quiescent HUVECs and strongly 
upregulated after exposure to fetal bovine serum. It down-regulates the 
anti-angiogenic homeobox protein GAX (growth arrest homeobox) and 
HoxA5, and functionally antagonizes the inhibitory effects of HoxA5 on 
tube formation in vitro[62]; 
mir-210 is induced by hypoxia in endothelial cells. Mir-210 over-expression 
enhanced the formation of capillary-like structures and VEGF-induced 
migration[63]; 
Mir-132 expression is induced by angiogenic growth factors, including 
VEGF-A and bFGF through the phosphorylation of CREB [64]. Moreover, 
over-expression of miR-132 increases EC proliferation and in vitro 
networking by targeting p120RasGAP, a GTPase-activating protein. 
 Anti-angiogenic microRNAs: 
Mir-221/222 inhibits tube formation, migration and wound healing of EC in 
vitro by targeting stem cell factor (SCF) receptor, c-kit. High glucose 
treatment of HUVECs induced expression of mir-221 and impaired cell 
migration and reduced expression of c-kit [59]; 
 
The role of the mir-17-92 cluster in angiogenesis is complex. In fact, mir-18a and 
mir-19a have been shown to target thrombospondin type 1 repeats (TSR) while 
mir-17-5p modulate EC migration and proliferation by targeting TIMP1. By contrast, 
both mir-20a and mir-92a seem to display anti-angiogenesis activity, targeting 
VEGF-a and integrin-5 (Figure 8). 
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Figure 8. Role of microRNAs in angiogenesis. The relationship between 
miRNAs and angiogenesis is bidirectional and it is possible to divide the endothelial 
miRNAs in three classes: 1) miRNAs that target genes involved in angiogenesis 
(AngiomiRs), 2) miRNAs whose expression can be modulated by pro-angiogenic 
stimuli, or 3) miRNAs whose expression can be modulated by anti-angiogenic 
stimuli.[65]  
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2. AIM OF THE WORK 
 
In patients with diabetes, particularly if complicated by ischemic foot lesions, the 
availability of EPCs is impaired. Different mechanisms may potentially reduce the 
abundance of circulating EPCs, including impaired mobilization, proliferation, 
and/or augmented cell loss by necrosis/apoptosis. Moreover, circulating EPCs from 
diabetic patients show altered function in in vitro assays of migration and 
incorporation into capillary networks. These quantitative and qualitative defects 
could contribute to the delayed healing of diabetic ulcers as well as to the 
increased incidence of post-angioplasty restenosis. At the present, however, it 
remains unknown whether the number of EPCs can be used as a prognostic 
biomarker.  
 
My project aims to determine the additive value of circulating EPCs in predicting 
major end-points such as mortality, amputation and post-angioplasty restenosis in 
diabetic patients with Critical Limb Ischemia (CLI). Furthermore, we aim to obtain 
mechanistic insights into diabetic progenitor cells impairment and to provide the 
first characterization of the EPC-associated miRNA with special respect to those 
potentially involved in the control of angiogenesis. 
 
The project has two major objectives:  
A) To validate the prognostic value of endothelial progenitor cells, identified by flow 
cytometric analysis of antigenic phenotype, in a cohort of 120 patients with type-2 
diabetes complicated by CLI. Endpoints are mortality, amputation and post-
angioplasty restenosis.  
B) To determine the mechanisms responsible for endothelial progenitor cell 
dysfunction in the perspective of new therapies for the cure of the diabetic foot. In 
particular we aim to investigate if the microRNA signature could identify high risk 
patients. 
 
Simultaneous analysis of quantitative and qualitative characteristics of circulating 
EPCs together with functional signatures of diabetes will allow us to create a 
cellular profile for prediction of clinical outcome. The biomarkers might be used 
alone or in combination on a larger scale in patients with initial skin lesions to 
recognise those that are more prone to develop foot complications.  
Compared with previous studies conducted on a limited number of patients, the 
present one was designed to have sufficient power to draw definitive conclusions 
on the patho-physiological and clinical relevance of endothelial progenitor cells in 
diabetic patients as compared with non-diabetic patients affected by foot problems. 
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3.  MATERIAL AND METHODS 
 
Sample size  
Since there are no data in the literature concerning the progenitor cells relation with 
the events considered here (amputations, restenosis, and new atherosclerotic 
plaques), it is impossible to estimate the number of patients necessary for a study 
of this kind. From a series of 993 diabetic patients Dr E. Faglia reported a 12% rate 
of post-angioplasty restenosis. The 5-year incidence for amputation is 84%. Since 
we don't know the relation between progenitor cells and events, we consider the 
situation that is described by prevalence of 50% (the most conservative on terms of 
sample size). On this basis we decided that the prevalence must have an accuracy 
of 5% with a probability to be showed of 95%. The number of patients calculated is 
= 91 + 18 (20% drop out) for a total of 109 patients. After one year from the 
beginning of the enrolment we decided to increase the number of diabetic patients 
to 120 due to 30% dropout at follow up visit.    
Since normal criteria are not already available, to conduct the functional analyses, 
we enrolled a group of 30 not-diabetic subjects with critical limb ischemia, age- and 
sex-matched to identify key changes to analyze in the entire group of patients. All 
patients enrolled were subjected to the same visits of the diabetic group. We also 
decided to include a third group of 23 healthy volunteers to investigate the role of 
ischemia in EPCs dysfunction. 
 
Inclusion Criteria 
Adult type 2 diabetic patients, both men and women, with chronic critical ischemia 
as defined by TASC 2007 criteria:  
Pain at rest, and/or ulcer or gangrene due to arteriopathy: transcutaneous oximetry 
< 30 mmHg or pressure on the ankle < 70 mmHg.  
Exclusion Criteria  
• Cancer with adverse prognosis in months, or chemotherapic treatment  
• Ongoing or planned pregnancy  
• Lack of consent to participate to the study 
Patient enrolment visit:  
General comprehensive visit (including: Chest RX, Rest ECG, and glycaemia plus 
glycosilated haemoglobin measurement) 
Ankle arterial pressure  
Angiographyc study and angioplasty in the same time  
At the enrolment visit and at follow up visit after 12 and 18 months Ecodoppler and  
Transcutaneous oximetry.  
Ulcer severity is measured applying the University of Texas Wound Classification 
(TUC) 
24 
 
EPCs isolation 
Blood samples (35ml) were obtained from a forearm vein and mononuclear white 
blood cells (MNC) separated on a Ficoll-Paque PLUS (Amersham Biosciences) 
gradient at 400g. Flow cytometry was used to determine the % of cells expressing 
respective cell surface antigens (CD45dim, CD34pos, CXCR4pos, KDRpos). 
Human MNCs were stained for surface antigen expression using combinations of 
the following  antibodies: anti-KDR-PE (R&D Systems), anti-CD45-APC-H7, anti-
CD34-PECy7, anti-CXCR4-APC (all BD Pharmingen). For each test, 5x10
5
 to 
2x10
6
 total events were analyzed. Fluorescence was analyzed in a FACSCanto 
flow cytometer using the FACSDiva software (both BD).  
For EPCs enrichment, 1x10
7 
MNC/well were plated on fibronectin (Sigma)-coated 
6-well plates (BD Falcon) and cultured in EBM-2, supplemented with EGM-2 MV 
SingleQuots and 10% FBS (EGM-2MV; Cambrex) for 4 days. 
 
Migration Assay 
To study directed migration, 5x10
6
 freshly isolated human MNC in 0.5 mL migration 
medium (EBM-2, 0.1 % BSA) were added in the top chamber of transwell migration 
inserts (Corning; diameter: 24mm, pore size 3µm) placed inside a 12-well plate. 
The lower chamber contained 1.2mL migration medium with SDF-1a (100ng/ml). 
Plain migration medium without SDF-1a was used as controls. The assay was 
stopped after 16h. After migration, non-migrated cells and migrated cells were 
analysed by flow cytometry to determine the % of cells expressing respective cell 
surface antigens (CD45dim, CD34pos, CXCR4pos, KDRpos). 
 
For EPCs migration assay, 5 μm pore-size filters-equipped transwell chambers 
(Corning) coated with fibronectin were used. Cells (75X10
3
) were placed in the 
upper chamber, and allowed to migrate toward SDF-1a (R&D) (100 ng/mL), FBS 
(10% in EBM medium) or BSA (control). 
The assays were stopped after 16 hours at 37°C, and cells that migrated through 
the filter were fixed on the lower side of the filter and mounted with Vectashield 
containing DAPI. Five random fields were counted at 20X magnification for each 
chamber. 
RNA extraction and Taq-Man quantitative real time  
RNA was extracted using Trizol reagent (Invitrogen) following the manufacturer‟s 
instructions. Concentration of the total RNA was determined by the Nanodrop 
ND1000 Spectrophotometer (Thermo Scientific and the size and integrity of RNAs 
were assessed using an Agilent 2100 Byoanalyzer.  
RNA reverse transcription to measure miRNAs was performed with the TaqMan  
miRNA reverse transcription kit using the manufacturer‟s instructions (Applied 
Biosystems). miR-15 and mir-16 expression was analysed by Applied 7900 Real 
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Time and normalized to the U6 small nucleolar RNA (snRU6). Each reaction was 
performed in duplicate. Quantification was performed by the 2
 
Ct method. 
Serum analysis was performed as described in  Kroh E et al. 2010[66]. 
microRNA transfection 
EPCs were transfected with 50nM pre-mirna mimics (pre mir-15a and pre-mir-16) 
or with 50nM mirna inhibitors (anti-mir-15a and anti-mir-16)(Applied Biosystems) 
using GeneSilencer (Dharmacon). The dose of mimics and inhibitors was selected 
based on dose response experiments. All experimental control samples were 
treated with an equal concentration of a non-targeting control mimic sequence, for 
use as control for nonsequence-specific effects in miRNA experiments. The 
efficiency of transfection was greater than 95% as assessed by transfection with 
fluorescently labeled miRNA mimic (mirna mimic-Pe-Cy3)(Applied Biosystems). 
Verification of the degree of miRNA overexpression and inhibition was determined 
using quantitative reverse transcription-polymerase chain reaction. 
Matrigel Assay 
Briefly, 50X10
3
 PHK67-labelled (Sigma) EPCs were added to 8 wells chamber 
slides pre-coated with 150µl Matrigel (Becton Dickinson), together with 50X10
3
 
Texas red-HUVEC in a total volume of 150µl EBM-2 0.1% BSA. After 16 hours 
incubation at 37°C, floating cells were removed by washing and capillary-like 
structures were fixed in 2% paraformaldehyde and mounted with DAPI containing 
fluorescence medium. The assays were performed in duplicate wells. Tube 
formation was measured by counting the number of intersection points 
(magnification 20X) in 5 random view fields photographed using a FITC-specific 
filter setting to concomitantly observe EPCs presence. 
Apoptosis assay 
Apoptosis was measured quantifying Annexin V positive cells by flow citometry 
analysis. Briefly, transfected EPCs were stained with 5ul of Annexin V (BD 
Biosciences) for 15min in the dark. After incubation,  Annexin V positive cells were 
resuspended in 150ul of Annexin Binding Buffer and assed using FACS Canto flow 
cytometer and FACS Diva Software (BD). 
Identification of target genes of mir-15 and mir-16 
To determine gene targets of mir-15 and mir-16, five leading miRNA target 
prediction algorithms (TargetScan 4.1, miRanda, miRDB, MirWalk, RNA22) were 
used. Western blots for BCL2, AKT3 and -actin were performed on EPCs lysates 
from patients or transfected EPCs. 
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Statistical analysis 
Demographic and background information are summarized and displayed using 
descriptive statistical techniques.  
Normality of data distribution was verified with Kolmogorov Smirnov test. 
Samples homogeneity was confirmed using Chi Square Pearson test for discrete 
variables and T- Student‟s test for independent sample for continuous variables. 
For categorical variables frequency tables are presented, for continuous variables 
descriptive statistics such as mean, median, standard deviation, IC  95%, 
minimum, maximum etc. are tabulated. 
A p value <0.05 was taken as statistically significant.  
Categorical variables were compared with the Chi Square test or Fisher‟s Exact 
test and Cochran Q or Mc Nemar test on the time.  
Statistical comparisons between initial and follow-up data for continuous variables 
were performed using Anova (Two way) test and the Wilcoxon signed rank test.  
T-test for independent sample and Mann–Whitney tests were used to compare the 
subgroups continuous variables.  
Analyses were performed with SPSS v.19 software. 
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4. RESULTS 
4.1 Study design 
The study has two objectives: 
I) To validate the prognostic value of EPCs, identified by flow cytometry analysis of 
antigenic phenotype, in a cohort of 120 patients with type-2 diabetes complicated 
by CLI. Events are mortality, amputation and post-angioplasty restenosis. 
Statistical intermediate analysis of the results obtained is reported in section 4.3. 
 
II) To determine the mechanisms responsible for EPC dysfunction. In particular we 
aim to investigate the expression of microRNA implicated in the regulation of 
vascular function. 
 
Two additional control groups have been added in the course of the study to define 
normal criteria for functional and molecular analyses. 
 
Hence, we have enrolled 3 groups of individuals: 
1) 120 out of 120 Diabetics patients with critical limb ischemia (CLI) 
2) 20 out of 30 Non diabetic ischemic patients with CLI 
3) 23 out of 23 Healthy subjects-controls (no follow up (FU)) 
 
In Table 3, demographic characteristics are summarized. 
 
 
Healthy (n=23) 
Non diabetic CLI 
(n=20) 
Diabetic CLI 
(n=120) 
Age, years 42+8 77+10 71+9 
Gender, male (%) 48% 55% 60% 
Diabetes year - - 18.6+11.9 
Table 3. Clinical features of all enrolled groups. Values are mean+S.D 
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4.2 Laboratory evaluations 
We received peripheral blood from all the patients enrolled in the study and 
performed experiments to evaluate the antigenic profile of isolated MNCs and their 
migratory ability. Figure 9 illustrates the experimental protocol. 
 
 
 
Figure 9. Scheme of the experimental plan. 
 
4.2.1 Phenotypic characterization of freshly isolated MNC 
Using ISHAGE guidelines, we performed flow cytometry analysis of CD34
pos
 and 
CD45
low
,CD34
pos
,CXCR4
pos
,KDR
pos
 cells (EPCs) from freshly isolated total MNCs 
of healthy controls (n=23), non diabetic CLI (n=19), diabetic CLI patients (n=120) 
(Figure 10).  
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Figure 10. Flow citometry strategy to detect EPCs. Based on ISHAGE 
guidelines we performed a flow citometry gating strategy to detect EPCs (red box). 
EPCs were defined as CD45l
ow
/CD34
pos
/CXCR4
pos
/KDR
pos 
Based on literature data, we decided to analyze these two MNCs subpopulation 
because it was demonstrated their involvement in reparative mechanism and also 
the impairment of their functionality caused by diabetes [67]. 
CD34 positive cells were reduced by ischemia (% CD34 positive cells: Healthy: 
0.1190±0.01, non diabetic CLI: 0.07±0.015, diabetic CLI:  0.084±0.006; *p<0.05 vs 
Healthy) but no differences were observed between patients with or without 
diabetes.  
Ischemia reduced the number of EPCs compared with healthy controls; 
surprisingly, diabetic CLI patients have higher EPC number compared with non 
diabetic CLI (Healthy: 0.04±0.012, non diabetic CLI: 0.007±0.001, diabetic CLI:  
0.021±0.002, *p<0.05 vs Healthy, #p<0,05 vs non diabetic CLI) (Figure 11). 
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Figure 11.  Progenitor cells analysis on total MNC. Flow cytometry 
quantification of CD34
pos
 (upper panel) and EPCs 
(CD45l
ow
/CD34
pos
/CXCR4
pos
/KDR
pos
) (lower panel) from healthy, non diabetic CLI 
and diabetic CLI patients. (*p<0.05 vs Healthy and #p<0,05 vs non diabetic CLI).  
Ischemia and diabetes impairs MNC migratory ability 
Transwell
 
migration assay was performed toward SDF-1 using total MNCs from 
healthy controls, non diabetic CLI or diabetic CLI patients.  We found a decrease of 
MNC migratory activity in ischemic patients with or without diabetes as compared 
with controls (% of SDF-1 mig cells vs vehicle: healthy: 2.1+0.11; non diabetic 
CLI: 1.57+0.1; diabetic CLI 1.43+0.05).  (Figure 12) 
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Figure 12. Migratory ability of MNCs. Upper panel Graphs illustrating MNCs 
migratory ability in the three groups enrolled. Lower Panel Bar graphs showing 
MNC migration index. Migration index was calculated as ratio between SDF-1 
migrated cells and BSA migrated cells. (*p<0.05 vs Healthy) 
 
Diabetes impairs SDF-1 driven EPCs enrichment 
We then verified whether CD34 positive cells and EPCs can be enriched from total 
MNCs
 
based on migratory response to SDF1-. After performing a transwell
 
migration assay toward SDF-1, we harvested
 
migrating and non-migrating cells 
from the lower
 
and upper chambers, respectively.  
SDF-1 stimulation resulted in a 1.7 and 1.3-fold enrichment of EPCs in the 
migrated fraction in healthy and non diabetic CLI respectively; whereas, the 
response of EPCs to SDF-1 was totally abrogated in diabetic patients (Figure 
13). We did not observe any difference in the percentage of CD34pos after 
migration in the three groups (data not shown).  
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Figure 13. Diabetes impairs SDF-1 induced EPC enrichment. Upper panel 
Scheme of flow citometry strategy to detect EPCs enrichment. Lower panel 
Quantification of MNCs after migration. Data are shown as ratio between migrated 
cells (mig) and not-migrated (non mig) cells to SDF-1 or vehicle. (*p<0,05 vs BSA). 
Diabetes does not de-regulate CXCR4 expression on MNCs 
In order to understand if diabetic EPCs impairment is due to lack of CXCR4, SDF-1 
receptor was quantified on the surface of MNCs that express EPC marker. Figure 
14 shows no difference among the two groups using flow cytometry. In line, no 
difference was also observed in mRNA levels and protein expression of cultured 
EPCs from the three groups. (data not shown) 
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Figure 14. Expression of CXCR4 in MNCs defined as EPCs.  Flow cytometry 
analysis of CXCR4 on MNCs from all the patients enrolled. Graphs bar are 
calculated as mean fluorescence intensity + s.e.m.  
 
Diabetes impairs the functions of cultured EPCs. 
Circulating MNCs give raise to endothelial-like cells in culture on fibronectin. These 
cells that co-express CD34/CD45/CD14/CXCR4/KDR[11], are named early culture 
EPCs. We investigated if diabetes induces alterations of early culture -EPC as 
described in literature. We analyzed EPC migratory ability in healthy individuals 
(n=5) and diabetic patients  (n=5) using FBS (Figure 15 upper panel) or SDF-1 as 
stimulus (Figure 15 lower panel).   
34 
 
 
H
ea
lth
y
D
ia
be
tic
 C
LI
0
5
10
15
20
BSA
FBS*
E
P
C
 m
ig
ra
te
d
 /
fi
e
ld
 
H
ea
lth
y
D
ia
be
tic
 C
LI
0
5
10
15
BSA
SDF-1*
E
P
C
 m
ig
ra
te
d
/f
ie
ld
 
Figure 15. Diabetes induces early culture EPCs migration impairment. Graph 
bar showing number of healthy (n=5) or diabetic (n=5) cultured-EPCs migrated 
cells vs FBS (upper panel) or SDF-1 (lower panel) (*p<0.05 vs BSA). 
Then we analyzed the capacity of early culture EPCs to induce capillary-like 
structures on a matrigel layer and we confirmed that diabetes causes EPC 
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impairment (Figure 16 left panel). We also observed an increase of apoptosis in 
diabetic cells compared with controls (Figure 16 right panel) 
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Figure 16. Diabetes induces early culture EPCs dysfunction. Left Panel. 
Graph bars shows a decrease in capillary like structure formation by HUVECs 
cocultured with diabetic EPCs. (*p<0.05 vs Healthy). Right Panel. Diabetes 
increases apoptosis of EPCs compared to healthy control (*p<0.05 vs Healthy). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
36 
 
4.3 Intermediate statistical analysis 
We here report the intermediate analysis performed on diabetic patients that 
reached the 12 month follow up visit by September 2011. 
Ninety-four out of one-hundred-twenty (94/120) diabetic patients enrolled to the 
study reached the 12 month follow up, and 58.5% had at least one event 
registered: restenosis or amputation or death (Table 4).  
 
 
 
  Events (# of total) 
Patients at FU 94 (58,5%)  
Restenosis  37 (39,36%)  
Amputation 10 (10,64%)  
Death 7 (7.45%)  
Restenosis-
amputation-death 
1 (1.06) 
No events 39 (41,49%) 
Table 4. Events registered at follow-up visit (September 2011). 
Percentage of events considering the total number of diabetic patients.  
 
For the purpose of the analysis the diabetic patients group has been subdivided in 
two subgroups of patient: 1) patients with at least one event (with event), and 2) 
patients with no events (no event). A detailed description of the patients‟ 
characteristics follows.  
 
Diabetic patients with an event were male for the 67.3%. No significant difference 
was observed considering gender variable (p values=1.00) (Table 5). 
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Gender With Events No events Total 
 n° % n° % n° % 
Male 37 67.27 27 69.23 64 68.09 
Female 18 32.73 12 30.77 30 31.91 
Total 55 100 39 100 94 100 
Table 5. Analysis of events distribution considering gender as a variable 
We did not find a significant association with age between  patients with or without 
events.   
Table 6 shows that no difference was observed also considering current anti-
diabetic treatments (p values =0.336). 
 
Terapy With Events No events Total 
  n° % n° % n° % 
Diet 3 5.45 2 5.13 5 5.32 
OH  
(Oral Hypoglycemic) 13 23.64 9 23.08 22 23.4 
Insulin 28 50.91 20 51.28 48 51.06 
Diet + Insulin 10 18.18 3 7.69 13 13.83 
Diet + OH + Insulin 1 1.82 2 5.13 3 3.19 
OH + Insulin 0 0 1 2.56 1 1.06 
OH + Diet 0 0 2 5.13 2 2.13 
Total 55 100 39 100 94 100 
Table 6. Analysis of events distribution using diabetic drugs as variable 
We also analyzed whether an association exists between other clinical parameters 
and the presence of events. We found no differences between patients with or 
without events when considering LDL (p value 0.834), HDL (p=0.272) and 
triglycerides levels (p=0.796). We found no association when considering smoke 
(p=0.696) 
 
We also considered if the co-existence of other diseases could be correlated to the 
occurrence of an event. However, as illustrated in Table 7 no one of these clinical 
conditions shows significant correlation with the events. 
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Clinical outcomes With Events No events Total 
Hypertension n° % n° % n° % 
No 26 47.27 10 25.64 36 38.3 
Yes 29 52.73 29 74.36 58 61.7 
Total 55 100 39 100 94 100 
CAD             
No 27 49.09 22 56.41 49 52.13 
Yes 28 50.91 17 43.59 45 47.87 
Total 55 100 39 100 94 100 
CVA             
No 48 87.27 34 87.18 82 87.23 
Yes 7 12.73 5 12.82 12 12.77 
Total 55 100 39 100 94 100 
CKD             
No 37 67.27 23 58.97 60 63.83 
Yes 18 32.73 16 41.03 34 36.17 
Total 55 100 39 100 94 100 
Retinopathy             
No 44 80 34 87.18 78 82.98 
Yes 11 20 5 12.82 16 17.02 
Total 55 100 39 100 94 100 
Neuropathy             
No 47 85.45 35 89.74 82 87.23 
Yes 8 14.55 4 10.26 12 12.77 
Total 55 100 39 100 94 100 
Table 7. Presence of other clinical diseases in diabetic patients group. List of 
disease in the table: CAD=Cardiovascular artery disease, CVA=cerebrovascular 
accident, CKD= Chronic Kidney Disease 
We also compared the values of Transcutaneous PO2 (TC) level, before and after 
Percutaneous Transluminal Angioplasty (PTA), a parameter that when increased 
confirms the success of the PTA procedure. We interestingly found significant 
difference before and after PTA in both of the two groups of patients (p<0.001) and 
also a difference (p=0.046) between TC level after PTA between group with or 
without events as reported in Table 8.  This data suggests that the improvement in 
perfusion after PTA is instrumental to a better outcome if associated to 
amelioration of oxygen diffusion, i.e. less severe microangiopathy.  
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TC PTA NUMBER  MEAN ST. DEV CONF. INTERVAL 
With Events PRE 38 17.53 11.01 13.91 21.15 
  POST 38 36.5 19.57 30.07 42.93 
No events PRE 25 20.36 10.21 16.15 24.57 
  POST 25 45.12 16 38.51 51.73 
Table 8. Values of TC levels before and after PTA in the two groups. 
Next, in the attempt to find a correlation between the number and function of EPC 
and the occurrence of the adverse events (first objective of the study), we analyzed 
the collected laboratory parameters vs. the events. As illustrated in Figure 17, 
analysis of the number of CD34pos MNCs and EPCs between diabetic patients 
with or without events did not show any significant difference.  
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Figure 17. Numbers of progenitors cells in diabetic patients with or without 
events. 
Statistical analysis revealed a significant difference considering the number of 
SDF-1 migrated cells compared to BSA migrated cells  (p<0.001). This result 
shows that, even if MNC isolated from diabetic patient are less responsive to SDF-
1 stimulus compared with healthy or non diabetic controls, they still migrate toward 
the chemoactractant. When we analyzed migration results, dividing patients with or 
without events we did not observe any significant difference. 
We also analyzed the number of CD34 positive cells of the MNC migrated fraction 
and we did not observe difference between patients with or without events.  
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Interestingly, the analysis of EPC number after migration revealed a significant 
increase in patients  with events (p=0.016), but only in the BSA migration fraction 
(Figure 18).  
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Figure 18. Analysis of EPCs number after migration in the diabetic groups.  
Although the above mentioned statistical significance was reached for the analysis 
of EPC BSA-migrated, we did not obtain significant results when we attempted to 
identify predictive values using logistic univariate regression. At the end of the 
study, when all the enrolled patients will reach the follow up and a larger number of 
events will be recorded, we expect to be able to perform this crucial analysis. 
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4.4 Mechanism of diabetic EPCs impairment: microRNAs 
Ischemia and diabetes de-regulate microRNAs signature 
In order to identify other mechanism that potentially explain EPCs impairment in 
diabetes we analyzed the expression of 29 different microRNAs in 4 days cultured 
EPCs from healthy and CLI patients with or without diabetes (n=5 for each groups) 
(Table 5).  
 Relative expression to snRU6 
 Healthy Non diabetic CLI Diabetic CLI 
Mir-1 1,404+ 0,58 1,293+1,19 1,408+0,58 
Mir-9 1,102+0,24 0,702+0,32 3,264+1,31 
Mir-15a 1,019+0,10 0,689+0,35 2,254+0,44 
Mir-15b 1,078+0,21 1,405+0,4 1,960+0,21 
Mir-16 1,041+0,15 0,73+0,25 1,962+0,27 
Mir-17 1,119+0,28 0,426+0,11 1,230+0,25 
Mir-18a 1,045+0,15 0,545+0,24 2,068+0,23 
Mir-19a 1,137+0,3 0,347+0,21 1,426+0,13 
Mir-19b 1,266+0,46 0,406+0,25 1,5+0,11 
Mir-20a 1,047+0,16 0,369+0,16 1,394+0,24 
Mir-23a 1,160+0,26 1,864+0,37 3,295+0,79 
Mir-24 1,076+0,26 0,835+0,18 1,956+0,18 
Mir-27b 1,008+0,06 1,052+0,5 2,794+0,67 
Mir-92a 1,083+0,19 0,636+0,25 0,724+0,1 
Mir-100 1,548+0,77 0,429+0,05 0,528+0,04 
Mir-103 1,10+0,19 1,405+0,49 2,882+0,61 
Mir-107 1,083+0,2 0,952+0,33 2,731+0,58 
Mir-126 1,197+0,28 0,304+0,14 0,980+0,27 
Mir-130a 1,073+0,21 0,841+0,41 1,207+0,4 
Mir-132 1,037+0,14 0,730+0,15 2,673+0,63 
Mir-195 1,044+0,15 0,464+0,21 1,163+0,16 
Mir-221 1,035+0,14 0,382+0,17 1,65+0,46 
Mir-222 1,133+0,28 0,219+0,05 0,319+0,06 
Mir-296 1,305+0,39 2,235+0,29 1,577+0,19 
Mir-424 1,027+0,12 0,628+0,28 2,335+1,12 
Mir-378 1,073+0,19 1,793+0,53 3,216+1,14 
Mir-497 1,129+0,27 0,341+0,13 0,386+0,1 
Mir-503 1,096+0,2 0,934+0,26 1,479+0,53 
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Table 9.  MicroRNAs levels in EPCs. Table shows the relative expression of mirs 
in EPCs (n=5 patients for each group). MicroRNA expression was normalized to 
snRU6 expression using the comparative Ct methods. Values are means +S.E.M. 
 
Ischemia up-regulates mir-15a, mir-16 and mir-221 expression in EPCs 
mRNAs. 
In different cancer cells, mir-15a and mir-16 cluster have been shown to play an 
important role in regulating cell proliferation and apoptosis by targeting genes 
involved in cell cycle progression [68]. Mir-15b and mir-16 have been shown to 
control the expression of VEGF in carcinoma cell lines [69]. In addition, mir-15b 
and mir-16 have also been shown to be differentially expressed in endometriosis, 
in which angiogenesis may be pathogenically involved [70]. Based on these data 
we decided to investigate the role of mir-15a and mir-16 in diabetic CLI EPCs. We 
performed mir-15a and mir-16 analysis on healthy (n=17), non diabetic CLI (n=16) 
and diabetic CLI (n=56).  We found an increase of these two microRNAs by 
ischemia (mir-15a 2-ddCt: healthy:1.4±0.3; non diabetic CLI: 7.7±1.9, diabetic CLI: 
5.19±0.8; p<0.05 vs Healthy; mir-16 2-ddCt: healthy:1.13±0.12; non diabetic CLI: 
4.51±1.13, diabetic CLI: 4.9±0.9; p<0.05 vs Healthy). Ischemia also induced the 
over-expression of mir-221 (mir-221-ddCt: healthy:1.25±0.19; non diabetic CLI: 
6.02±1.6, diabetic CLI: 5.15±1.04; p<0.05 vs Healthy). This microRNA is potentially 
involved in anti-angiogenic mechanisms and previous studies also demonstrated 
that this miRNA is involved in c-kit down-regulation. (Figure 19)  
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Figure 19. Ischemia significantly increases mir-15a, mir-16 and mir-221 levels 
in EPCs compared to healthy controls. Relative expression of mirs in EPCs. 
MicroRNA expression was normalized to snRU6 expression using the comparative 
Ct methods. Values are means +S.E.M (*p<0.05 vs Healthy). 
 
 
Mir-15a, mir-16 and mir-221 are all up-regulated in the circulation of ischemic 
patients with or without diabetes. 
Circulating microRNAs levels have been used for diagnostic and prognostic 
purposes. We analyzed circulating microRNAs levels in serum from all enrolled 
patients. Ischemia increases serum levels of mir-15a (2-ddCt: healthy:0.99±0.15; 
non diabetic CLI: 6.89±1.23; diabetic CLI:7.81±1.25; *p<0.05 vs Healthy) mir-16 (2-
ddCt: healthy: 1.14±0.19; non diabetic CLI: 2.82±0.63; diabetic CLI:3.87±0.52; 
*p<0.05 vs Healthy) and mir-221 (2-ddCt: healthy: 1.03±0.18; non diabetic CLI: 
3.46±0.56; diabetic CLI:3.24±0.43; *p<0.05 vs Healthy)  (Figure 20). 
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Figure 20. Serum levels of mir-15, mir-16 and mir-221 are up-regulated by 
ischemia.  Relative expression of serum microRNAs. MiRNA expression was 
normalized to exogenous cel-mir-39 expression using the comparative Ct methods. 
Values are means +S.E.M (*p<0.05 vs Healthy). 
 
Mir-15/16 over-expression effect on EPCs functionality (migration, apoptosis 
and pro-angiogenic capacities) 
To investigate the functional relevance of mir-15 and mir-16 in EPCs, we 
transfected pre-microRNA in healthy EPCs.  
After confirmation of microRNAs over-expression by qPCR analysis (Figure 21), 
we performed migration assays using unspecific stimulus, FBS, or a specific 
stimulus, SDF-1. We observed that only combined mir-15 and mir-16 co-
expression blocks FBS-induced (n=5) and SDF-1 (n=5)  driven EPC migration. 
(Figure 22)  
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Figure 21. Pre-mir transfection increases mir-15 and mir-16 expression in 
healthy EPCs. Relative expression of mir-15a and mir-16 in EPCs (n=3) after 
transfection.  MicroRNA expression was normalized to snRU6 expression using the 
comparative Ct methods. Values are means +S.E.M (*p<0.05 vs Healthy).  
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Figure 22. Mir-15 and mir-16 over-expression inhibits EPCs migration. Graph 
bars show number of migrated cells vs FBS (upper panel) or SDF-1 (lower panel) 
compared to vehicle. We performed experiments on five different donors. For each 
conditions migrated cells were counted in five random fields (*p<0.05 vs BSA). 
 
Then, based on literature data showing that mir-15a and mir-16 regulate cell 
survival in cancer cell lines, we investigated if mir-15 and mir-16 could induce 
EPCs apoptosis. After transfection of healthy EPCs, we analyzed the percentage of 
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Annexin V positive cells by flow cytometry. We found that mir-15/16 over-
expressing EPCs have higher abundance of Annexin V expression as compared to 
EPCs transfected with the control vector (SCR). (Figure 23) 
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Figure 23. Mir 15/16 increases apoptosis. Flow cytometry quantification of 
apoptosis in transfected EPCs. Ten different donors were studied (*p<0.05 vs 
scrambled). 
 
Finally, we investigated if mir-15 and mir-16 expression can modulate the pro-
angiogenic activity of EPCs. For this purpose, we performed co-culture of 
microRNA over-expressing EPCs with HUVEC on a matrigel layer. We did not 
observe any significant difference compared with scramble control. (Figure 24)  
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Figure 24. mir-15/16 expression does not alter EPC pro-angiogenic in vitro 
activity. Graph bar indicating number of intersections of endothelial network on 
matrigel layer (n=5). 
 
AKT3 is a direct target of Mir-15/16 cluster. 
Bionformatic analyses predict BCL2, VEGF-a, AKT3 to be target genes of miRNA-
15a and -16, which would suggest anti-angiogenic and pro-apoptotic activities of 
these miRNAs. All these genes have been validated as direct targets of mir-15 and 
mir-16 [71].  
Target genes analysis on EPC lysates from the three groups demonstrates AKT3 
down-regulation in ischemic patients both at mRNA (n=5 for each groups) and 
protein level (n=3 for each groups) as compared to controls (Figure 25).  
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Figure 25. Mir-15 and mir-16 targets AKT3 expression. Left Panel. We 
analyzed AKT3 mRNA relative expression by qPCR on RNA extracted from EPCs 
of the three different groups (n=5 for each group). Right panel, we confirmed 
AKT3 down-regulation by Western blot analysis (n=3 for each group). AKT3 protein 
levels were normalized by -actin analysis (*p<0.05 vs Healthy). 
Protein analysis of EPCs lysates revealed no difference in BCL2 expression both in 
patients and in microRNAs over-expressing EPCs. 
Then, we investigated if similar effects are produced by mir-15/16 overexpression. 
As expected, over-expression of mir-15/16 in healthy EPCs down-regulated AKT3 
only at protein level. (Figure 26). 
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Figure 26. mir-15/16 down-regulates protein levels of AKT3. Quantification of 
AKT3 expression in transfected EPCs normalized by -actin Data is mean of four 
different experiments. (*p<0.05 vs Healthy). 
50 
 
No difference was observed in BCL2 expression after up-regulation of mir-15/16 
(data not shown). 
 
Inhibition of mir-15/16 rescues diabetic EPC migratory capacity.  
To investigate if microRNA down-regulation could restore diabetic EPC migratory 
ability, we transfected EPCs with oligo anti-mir 15/16.  After confirmation of mir-15 
and mir-16 inhibition by qPCR (Figure 27), we performed in vitro migration on 
diabetic EPCs. 
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Figure 27. Co-trasfection of diabetic EPCs with antimirs down-regulates mir-
15a and mir-16 expression. Co-trasfection of both anti-microRNAs reduced 
selected microRNAs expression in diabetic EPCs as compared to scrambled cells. 
Three different experiments were performed and analyzed by qPCR. 
We observed that only co-transfection of mir-15 and mir-16 rescues FBS or SDF-1-
induced migration of diabetic EPCs. (Figure 28) 
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Figure 28.  Down-regulation of mir-15/16 rescues diabetic EPCs migration.  
Graph bar indicated diabetic EPC migration versus FBS (upper panel) or SDF-1 
(lower panel) compared to scramble. Seven different patients were studied. 
(*p<0.05 vs BSA) 
To verify if down-regulation has also an effect on diabetes-induced apoptosis, we 
analyzed the number of Annexin V positive cells. We didn‟t observe any difference 
after antimirs transfection (Figure 29). 
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Figure 29. Analysis of apoptosis after microRNAs downregulation. We 
performed flow cytometry analysis on diabetic EPCs (n=10) after transfection of 
anti-mir 15 and mir-16. Apoptosis was evaluated by flow citometry as number of 
Annexin V positive cells compared to cell transfected with scrambled miRNA. 
Next we investigated if miRNAs inhibition has an effect on diabetic EPC angiogenic 
capacity. Again, down-regulation of mir-15 and mir-16 in diabetic EPCs (n=5) 
showed no difference compared to scramble (Figure 30). 
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Figure 30. Pro-angiogenic analysis on anti-mir transfected EPC. Pro-
angiogenic capacity was measured as number of intersections in five random 
fields. We didn’t observe any significant difference in matrigel assays. 
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5. DISCUSSION 
 
Diabetic foot ulcers represent a serious medical and socio-economic problem 
throughout the world. Foot problems are associated with significant mortality, 
morbidity, disability and impairment in the patient's quality of life. Furthermore, 
despite of the considerable resources devoted to the care of diabetic 
complications, treatment of the diabetic foot remains an unmet clinical need. 
Revascularization of the diabetic foot is often complicated by restenosis and 
thrombosis events, which account for the excess of limb amputation. Considering 
the impact on the patient wellbeing of the consequences of such peripheral 
vascular complications, early diagnosis and new therapeutic strategies are of 
paramount importance.  
To date prediction of clinical outcome of the ischemic foot relies on clinical data, 
including the presence or absence of ischemia, infection, footwear
 
and pressure 
relief, and overall glycemic control. Although these methods represent to date the 
best predictors for major disease outcomes, e.g. amputation, none of these data 
reflects the activity of endogenous repair mechanisms. In particular, EPCs 
availability and functionality are relevant to vascular repair. It was demonstrated 
that in diabetic patients the availability of EPCs is impaired [19, 21]. Different 
mechanisms could potentially reduce the abundance of EPCs, including impaired 
mobilization, proliferation, and apoptosis [18]. 
 
During these years, growing attention is focusing on the possibility of using EPCs 
as biomarker to predict vascular disease. Fadini et al. demonstrated that the low 
abundance of CD34 subfraction of MNCs is associated to cardiovascular risk. They 
hypothesized that progenitor cells count may be used as a surrogate marker of 
cardiovascular disease [72]. Other groups showed a correlation between progenitor 
cells and other diseases as cancer [73] or dystrophy [74]. 
 
The goal of this study is to determine the additive value of circulating EPCs in 
predicting major end-points such as mortality, amputation and post-angioplasty 
restenosis in diabetic patients with Critical Limb Ischemia (CLI). Moreover, we 
aimed to obtain mechanistic insights into diabetic progenitor cells impairment and 
to provide the first characterization of the EPC-associated miRNA with special 
respect to those potentially involved in the control of angiogenesis. 
Since normal criteria to conduct functional and molecular analyses were not 
already available, we enrolled two control groups represented by 1) a group of not-
diabetic CLI subjects, and 2) a group of healthy volunteers.  
 
We need to wait the end of the 12 month follow up (FU) to assess the first objective 
(to determine the prognostic value of circulating EPCs in the development of 
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diabetic foot complications, namely mortality, amputation and post-angioplasty 
restenosis). This thesis reports therefore an ad interim analysis of the data.  
To date, about 60% of patients have reached one year FU visit and we have 
registered 37 restenosis, 10 major amputations and 7 death events. About 42% of 
diabetic patients have no events recorded. Results showed no statistically 
significant differences in the number of antigenically defined EPCs between 
complicated (with at least one event) and not complicated (no event) diabetic 
patients. No difference in the overall migration capacity was observed between the 
latter two groups. Interestingly, our preliminary data showed a significant increase 
in the basal migration of EPC in patients with event vs. patients with no event. This 
result will need to find confirmation when all the FU data will be available at the end 
of the study. Preliminarily, we propose that the unspecific motility associated with 
altered directed migration may be indicative of the incapacity of the cells to find 
their way to injured tissues thereby compromising the healing process. Lack of 
directional migration associated to increased motility has been referred to alteration 
in cell polarization and dysfunction of the molecular migratory apparatus[75]. 
 
While awaiting for exhaustive and final statistical analysis, we performed an overall 
analysis of EPC characteristics. To obtain a detailed description of diabetic EPCs 
number and function, we further analyzed EPC isolated from the three study 
groups: diabetic CLI, non diabetic CLI, and healthy subjects. Since diabetes 
mellitus has been shown to adversely affect EPCs‟ number [76], we first measured 
the percentage of antigenically-selected MNCs subpopulations with pro-angiogenic 
potential by flow cytometry and observed a decrease in CD34
pos
 and EPCs in 
ischemic patients as compared to healthy. These results are in line with data 
published also by other groups [19, 77]. Unexpectedly however, diabetic patients 
showed a higher percentage of progenitor cells compared with non diabetic 
controls. Migration assay showed an impairment of cell motility in chronic limb 
ischemic patients with or without diabetes compared to healthy subjects. Migration 
assay results showed an enrichment of EPCs in the controls only; these data are in 
line with those previously published on an altered migratory function of EPCs from 
diabetic patients.[7]  
Next we confirmed that early culture diabetic EPCs show migratory and pro-
angiogenic dysfunctions compared to healthy EPCs [18]. Recruitment and 
incorporation of EPCs into ischemic tissues requires a coordinated sequence of 
multistep adhesive and signaling events including chemoattraction, adhesion, and 
transmigration, and finally the repair of the ischemic injury. Chemoattraction is the 
fundamental mechanism for the recruitment of progenitor cells to the ischemic or 
injured tissue. Various studies examined the factors attracting circulating EPCs to 
the ischemic site. Indeed, SDF-1 has been proven to stimulate recruitment of 
progenitor cells to the ischemic tissue [34]. These considerations and our present 
data demonstrate that impairment of diabetic EPCs migratory ability does not 
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permit the recruitment of these cells into ischemic tissue and potentially causes the 
failure of wound healing process in diabetic foot lesions. 
Mechanisms underlying the reduction of EPCs in diabetes are largely unknown. 
Weak bone marrow mobilization, impaired peripheral differentiation, and short 
survival in peripheral blood are all candidates. Several mobilizing factors, such as 
granulocyte colony-stimulating factor (G-CSF), stromal cell derived factor-1 (SDF-
1), vascular endothelial growth factor (VEGF) via AKT protein kinase pathway 
activation and endothelial nitric oxide synthase (eNOS), were demonstrated to 
mediate EPCs‟ mobilization, proliferation, and migration. 
We therefore attempted to investigate the mechanisms involved in this impairment. 
Kucia and colleagues also demonstrated that SDF-1 and its receptor CXCR4, play 
a critical role in regulating hematopoietic cell trafficking [78]. Based also on work of 
Zheng and collaborators we analyzed the expression of SDF-1 receptor, CXCR4, 
on EPCs identified by flow cytometry in the total MNCs population. After 
demonstration that the migration deficit was not dependent on a decrease in the 
CXCR4 cytokine receptor on the surface of EPCs we focused on mechanisms of 
intracellular signalling.  
 
Role of microRNAs in diabetic EPC disfunction. 
Recently, miRNAs have been shown to regulate EC functions, including 
proliferation, migration and assembling in branched networks. Caporali et al., 
published that diabetes up-regulated mir-503 which modulates EC function. 
Another group demonstrated that mir-34 is involved in EPCs impairment in 
cardiovascular disease [79]. We therefore considered an involvement of 
microRNAs in the modulation of EPCs angiogenic capacity in diabetes. To this aim, 
we performed a preliminary screening on EPCs from the patients enrolled and 
demonstrated that diabetes and also ischemia induce specific microRNAs de-
regulation compared with healthy controls. 
Next, we selected two miRNAs, mir-15a and mir-16 based on their already known 
role in controlling migratory and apoptotic mechanisms in cancer [71, 80, 81]. To 
investigate the role of mir-15a and mir-16, we transfected these miRNAs into 
healthy EPCs. We then analyzed cell functionality in migration and angiogenic 
assays. We observed, for the first time, that only co-expression of mir-15a/16 
blocks SDF-1 induced migration in EPCs but single pre-mir-15 or -16 transfection 
does not modulate EPCs migration underlying a possible cell compensatory 
mechanism when only one microRNA is over-expressed.  
To confirm that this impairment of migration was not SDF-1-receptor-dependent we 
used an unspecific stimulus, FBS, for migration and we obtained the same results. 
We also demonstrated that mir-15 and mir-16 together induce EPCs apoptosis but 
no difference was observed in the pro-angiogenic capacity of these cells in a 
matrigel assay.  
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Next, we focused our interest on the involvement of these two microRNAs in 
diabetic migratory dysfunction.  We investigated if down-regulation of mir-15a/16 
could restore diabetic EPC migratory ability. Interestingly, we observed that 
inhibition of both mir-15a/16 rescued FBS and SDF-1 induced migration; but no 
effect was observed in apoptotic and angiogenic assay.  
Our data demonstrate that inhibition of microRNAs expression could potentially 
increase the recruitment of diabetic EPCs in the ischemic tissues to repair the 
injury. 
Bionformatic analyses predict BCL2, VEGFA and AKT3 to be target genes of 
miRNA-15a and -16, which support an anti-angiogenic and pro-apoptotic role of 
these miRNAs. In diabetic EPCs and mir over-expressing EPCs, we found a down-
regulation of AKT3, a protein involved in many EPCs functions like cell cycle 
progression, migration and survival.  Our data suggest that the regulation of this 
protein is at a post-transcriptional level because  AKT3 mRNA levels were not 
affected after microRNA over-expression. 
Recently, Chamorro et al demonstrated that mir-16 and 424, which share targets 
genes with mir-15, may participate in the control of angiogenesis in multiple ways 
[82]. They demonstrated that those miRNas also modulate the expression of KDR, 
FGFR1 and VEGF. Based on this evidence, we propose further functional studies 
to validate predicted target genes and correlate the expression changes with EPCs 
dysfunction in diabetes. In particular, we propose to investigate pathways like 
AKT/eNOS that could explain EPCs impairment due to diabetes.  
 
In conclusion, EPCs have recently generated considerable attention as potential 
novel prognostic biomarkers for vascular integrity, and therapeutic clinical 
approaches using these cells are ongoing. In this scenario, this study newly 
demonstrates that the spontaneous migration ability of a well antigenically 
characterized MNCs subpopulation of cells with EPC phenotype is significantly 
increased in diabetic patients that manifest at least one major adverse event 
(restenosis, amputation, and/or death). This is the first evidence generated in a 
clinical trial that EPC migration could be used as prognostic marker for diabetic 
vascular complications, thus opening the way to future clinical use of EPC as new 
biomarker for disease progression. We believe that at the end of the study, the 
analysis of the follow up data generated on the entire patient cohort will enable us 
to generate crucial data on the a new EPC-associated risk for diabetic CLI patients 
to develop life-threatening vascular complications. 
 
Second, we showed for the first time that miRNA 15 and 16 are crucial regulators 
of diabetic EPC pro-angiogenic functions. miRNAs have tremendous therapeutic 
potential for the treatment of vascular diseases associated with aberrant 
pathological angiogenesis.  
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FUTURE PERSPECTIVES  
We hypothesize, based on literature data and our own results, that hyperglycaemia 
and diabetes modulate the expression of microRNAs, like mir-15a and mir-16 in 
EPCs. These expressional changes may be relevant for induction of alteration in 
the paracrine capacity. Therefore, measurement of growth factors and cytokines in 
conditioned medium is a matter of future research. 
In addition, we plan to investigate the anti-angiogenic action of mir-221 in EPCs. 
Preliminary results showed that in diabetic EPCs mir-221 is over-expressed and its 
validated target gene, the stem cell factor (SCF) receptor, c-kit, is down-modulated. 
Hence, migration towards SCF and pro-angiogenic assay are considered in the 
future to investigate the importance of this microRNA in EPCs functionality. Next 
we will perform mir-221 over-expression or down-regulation on healthy or diabetic 
EPCs respectively.  
 
In conclusion, the identification of miRNAs regulating angiogenesis might be a 
meaningful approach for therapy. Thus, we hypothesize in the future that the use of 
miRNA mimics may be an attractive provasculogenic strategy to implement 
recovery of ischemic tissues. Interestingly, there is now direct evidence that 
synthetic miRNA mimics can be systemically delivered [83] and support the 
promise of miRNAs as a future targeted therapy for diabetic vascular 
complications. 
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